352
Views
26
CrossRef citations to date
0
Altmetric
Original Articles

TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma

ORCID Icon, , , ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 1433-1440 | Received 07 Sep 2020, Accepted 10 Oct 2020, Published online: 25 Oct 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Sally Temraz, Rihab Nasr, Deborah Mukherji, Firas Kreidieh & Ali Shamseddine. (2022) Liquid biopsy derived circulating tumor cells and circulating tumor DNA as novel biomarkers in hepatocellular carcinoma. Expert Review of Molecular Diagnostics 22:5, pages 507-518.
Read now
Song Wan, Xuan Liu, Wei Hua, Ming Xi, Yulin Zhou & Yueping Wan. (2021) The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer. Bioengineered 12:1, pages 1495-1504.
Read now

Articles from other publishers (24)

Inah Marie C. Aquino & Devis Pascut. (2024) Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma care. Annals of Hepatology 29:2, pages 101176.
Crossref
Sihao Du, Ke Cao, Yadong Yan, Yupeng Wang, Zhenshun Wang & Dongdong Lin. (2023) Developments and current status of cell‐free DNA in the early detection and management of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 39:2, pages 231-244.
Crossref
Aurélie Beaufrère, Sarah Paisley, Ibrahima Ba, Samira Laouirem, Victoria Priori, Hélène Cazier, Loëtitia Favre, François Cauchy, Mickael Lesurtel, Julien Calderaro, Caroline Kannengiesser & Valérie Paradis. (2023) Differential diagnosis of small hepatocellular nodules in cirrhosis: surrogate histological criteria of TERT promoter mutations . Histopathology 84:3, pages 473-481.
Crossref
Thomas Bardol, Georges-Philippe Pageaux, Eric Assenat & Catherine Alix-Panabières. (2024) Circulating Tumor DNA Clinical Applications in Hepatocellular Carcinoma: Current Trends and Future Perspectives. Clinical Chemistry 70:1, pages 33-48.
Crossref
Raquel Carrasco, Mercedes Ingelmo-Torres, Ramón Trullas, Fiorella L. Roldán, Leonardo Rodríguez-Carunchio, Lourdes Juez, Joan Sureda, Antonio Alcaraz, Lourdes Mengual & Laura Izquierdo. (2023) Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer. International Journal of Molecular Sciences 24:23, pages 16578.
Crossref
Sravan Jeepalyam, Ankur Sheel, Aslam Ejaz, Eric Miller & Ashish Manne. (2023) Is Cell-Free DNA Testing in Hepatocellular Carcinoma Ready for Prime Time?. International Journal of Molecular Sciences 24:18, pages 14231.
Crossref
Zeno Spârchez, Rareș Crăciun, Iuliana Nenu, Lavinia Patricia Mocan, Mihaela Spârchez & Tudor Mocan. (2023) Refining Liver Biopsy in Hepatocellular Carcinoma: An In-Depth Exploration of Shifting Diagnostic and Therapeutic Applications. Biomedicines 11:8, pages 2324.
Crossref
Joao Manzi, Camilla O. Hoff, Raphaella Ferreira, Renata Glehn-Ponsirenas, Gennaro Selvaggi, Akin Tekin, Christopher B. O’Brien, Lynn Feun, Rodrigo Vianna & Phillipe Abreu. (2023) Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant. Cancers 15:12, pages 3165.
Crossref
E. A. Antropova, T. M. Khlebodarova, P. S. Demenkov, A. S. Venzel, N. V. Ivanisenko, A.  D.  Gavrilenko, T.  V. Ivanisenko, A. V. Adamovskaya, P. M. Revva, I. N. Lavrik & V. A. Ivanisenko. (2023) Computer analysis of regulation of hepatocarcinoma marker genes hypermethylated by HCV proteins. Vavilov Journal of Genetics and Breeding 26:8, pages 733-742.
Crossref
Robert C. JacksonRobert C. Jackson. 2023. Evolutionary Dynamics of Malignancy. Evolutionary Dynamics of Malignancy 223 243 .
Zheyu Zhou, Xiaoliang Xu, Yang Liu, Qiaoyu Liu, Wenjie Zhang, Kun Wang, Jincheng Wang & Yin Yin. 2023. Liquid Biopsies. Liquid Biopsies 213 225 .
Sophie Schlosser, Deniz Tümen, Barbara Volz, Katja Neumeyer, Niklas Egler, Claudia Kunst, Hauke Christian Tews, Stephan Schmid, Arne Kandulski, Martina Müller & Karsten Gülow. (2022) HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice. Frontiers in Oncology 12.
Crossref
Raquel Carrasco, Mercedes Ingelmo-Torres, Ascensión Gómez, Ramón Trullas, Fiorella L. Roldán, Tarek Ajami, Davinia Moreno, Leonardo Rodríguez-Carunchio, Antonio Alcaraz, Laura Izquierdo & Lourdes Mengual. (2022) Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer. International Journal of Molecular Sciences 23:19, pages 11732.
Crossref
Maria Pallozzi, Natalia Di Tommaso, Valeria Maccauro, Francesco Santopaolo, Antonio Gasbarrini, Francesca Romana Ponziani & Maurizio Pompili. (2022) Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Cancers 14:19, pages 4631.
Crossref
Taehee Lee, Piper A. Rawding, Jiyoon Bu, Sunghee Hyun, Woosun Rou, Hongjae Jeon, Seokhyun Kim, Byungseok Lee, Luke J. Kubiatowicz, Dawon Kim, Seungpyo Hong & Hyuksoo Eun. (2022) Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC). Cancers 14:9, pages 2061.
Crossref
Ke Ye, Qinqiao Fan, Mingming Yuan, Dong Wang, Liang Xiao, Guo Long, Rongrong Chen, Tongdi Fang, Zengbo Li & Ledu Zhou. (2022) Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma. Frontiers in Oncology 12.
Crossref
Tejaswini Reddy, Abdullah Esmail, Jenny C. Chang, Rafik Mark Ghobrial & Maen Abdelrahim. (2022) Utility of Cell-Free DNA Detection in Transplant Oncology. Cancers 14:3, pages 743.
Crossref
Radhika Tippani, Sirisha Kalam, Srinivas Podeti & Mahendar Porika. 2022. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma 181 197 .
Yan Li, Yuanyuan Zheng, Liwei Wu, Jingjing Li, Jie Ji, Qiang Yu, Weiqi Dai, Jiao Feng, Jianye Wu & Chuanyong Guo. (2021) Current status of ctDNA in precision oncology for hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Stine Karlsen Oversoe, Michelle Simone Clement, Britta Weber, Henning Grønbæk, Stephen Jacques Hamilton-Dutoit, Boe Sandahl Sorensen & Jens Kelsen. (2021) Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. BMC Cancer 21:1.
Crossref
Panagiota Maravelia, Daniela Nascimento Silva, Giulia Rovesti, Michael Chrobok, Per Stål, Yong-Chen Lu & Anna Pasetto. (2021) Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. Cancers 13:17, pages 4334.
Crossref
Zhouhong Ge, Jean C.A. Helmijr, Maurice P.H.M. Jansen, Patrick P.C. Boor, Lisanne Noordam, Maikel Peppelenbosch, Jaap Kwekkeboom, Jaco Kraan & Dave Sprengers. (2021) Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma. Translational Oncology 14:7, pages 101073.
Crossref
Filippo Pelizzaro, Romilda Cardin, Barbara Penzo, Elisa Pinto, Alessandro Vitale, Umberto Cillo, Francesco Paolo Russo & Fabio Farinati. (2021) Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?. Cancers 13:9, pages 2274.
Crossref
Ismail Labgaa, Augusto Villanueva, Olivier Dormond, Nicolas Demartines & Emmanuel Melloul. (2021) The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers 13:4, pages 659.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.